Garnet Equity Capital Holdings Inc. Takes $3.68 Million Position in Bristol-Myers Squibb (BMY)

Garnet Equity Capital Holdings Inc. acquired a new position in shares of Bristol-Myers Squibb (NYSE:BMY) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 60,000 shares of the biopharmaceutical company’s stock, valued at approximately $3,677,000. Bristol-Myers Squibb comprises about 2.9% of Garnet Equity Capital Holdings Inc.’s holdings, making the stock its 17th biggest holding.

A number of other hedge funds have also recently modified their holdings of BMY. UBS Asset Management Americas Inc. grew its position in shares of Bristol-Myers Squibb by 10.0% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 4,791,226 shares of the biopharmaceutical company’s stock valued at $266,967,000 after buying an additional 434,072 shares during the last quarter. Van ECK Associates Corp grew its position in shares of Bristol-Myers Squibb by 3.9% in the 2nd quarter. Van ECK Associates Corp now owns 785,824 shares of the biopharmaceutical company’s stock valued at $43,786,000 after buying an additional 29,369 shares during the last quarter. Beaumont Financial Partners LLC grew its position in shares of Bristol-Myers Squibb by 50.5% in the 2nd quarter. Beaumont Financial Partners LLC now owns 11,231 shares of the biopharmaceutical company’s stock valued at $626,000 after buying an additional 3,769 shares during the last quarter. D.A. Davidson & CO. boosted its position in shares of Bristol-Myers Squibb by 0.6% during the 2nd quarter. D.A. Davidson & CO. now owns 189,479 shares of the biopharmaceutical company’s stock valued at $10,557,000 after purchasing an additional 1,092 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Bristol-Myers Squibb by 3.9% during the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock valued at $1,339,612,000 after purchasing an additional 910,496 shares in the last quarter. Institutional investors and hedge funds own 71.51% of the company’s stock.

How to Become a New Pot Stock Millionaire

BMY has been the topic of several research analyst reports. Zacks Investment Research lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Vetr lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 target price on the stock. in a research report on Thursday, December 28th. Morgan Stanley upgraded Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $51.56 to $78.00 in a research report on Thursday, February 15th. BMO Capital Markets restated a “sell” rating and set a $52.00 target price on shares of Bristol-Myers Squibb in a research report on Monday, January 22nd. Finally, Leerink Swann upped their target price on Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a research report on Tuesday, February 6th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average price target of $66.68.

BMY stock opened at $60.88 on Friday. Bristol-Myers Squibb has a fifty-two week low of $51.56 and a fifty-two week high of $70.05. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55. The company has a market cap of $101,726.25, a P/E ratio of 20.23, a PEG ratio of 1.62 and a beta of 0.96.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The business had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.35 billion. During the same period in the prior year, the business earned $0.63 EPS. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. equities research analysts forecast that Bristol-Myers Squibb will post 3.22 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.63%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 53.16%.

ILLEGAL ACTIVITY WARNING: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3340196/garnet-equity-capital-holdings-inc-takes-3-68-million-position-in-bristol-myers-squibb-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Reata Pharmaceuticals  Raised to “Sell” at BidaskClub
Reata Pharmaceuticals Raised to “Sell” at BidaskClub
Territorial Bancorp  Stock Rating Lowered by BidaskClub
Territorial Bancorp Stock Rating Lowered by BidaskClub
VSE  Upgraded at BidaskClub
VSE Upgraded at BidaskClub
Credit Suisse Group Raises Snap  Price Target to $21.00
Credit Suisse Group Raises Snap Price Target to $21.00
Zacks Investment Research Lowers NVR  to Sell
Zacks Investment Research Lowers NVR to Sell
Bristol-Myers Squibb’s  Hold Rating Reiterated at Cowen
Bristol-Myers Squibb’s Hold Rating Reiterated at Cowen


© 2006-2018 Ticker Report. Google+.